首页 > 最新文献

Seizure-European Journal of Epilepsy最新文献

英文 中文
The impact of sleep disorders on quality of life in patients with epilepsy 睡眠障碍对癫痫患者生活质量的影响
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-17 DOI: 10.1016/j.seizure.2025.04.012
Xiang Huang , Yingying Zhang , Qiuxing Lin , Kailing Huang , Yuming Li , Peiwen Liu , Danyang Cao , Wenhao Li , Wei Li , Dong Zhou , Dongmei An

Objective

We aimed to explore the prevalence of sleep disorders and their impact on the quality of life (QoL) in patients with epilepsy (PWE) in western China.

Methods

This cross-sectional study included PWE aged ≥14 years who were assessed using QoL in epilepsy-31 inventory (QOLIE-31), Insomnia Severity Index (ISI), STOP-BANG questionnaire, Epworth sleepiness scale (ESS), Pittsburgh sleep quality index (PSQI), Chinese version of Neurological Disorders Depression Inventory for Epilepsy (CNDDI-E) and Generalized Anxiety Disorder-7 (GAD-7). The impact of sleep disorders, depression and anxiety on all aspects of QOLIE-31 scores in PWE were assessed.

Results

A total of 458 PWE were enrolled. Mean QOLIE-31 score was 51.27±9.69. Relevant assessment scales showed that 10.3 % of the patients suffered from insomnia, 12.9 % of the cohort had a high risk of obstructive sleep apnea (OSA), 33.0 % of the patients had excessive daytime sleepiness (EDS), 48.0 % of the patients reported poor sleep, while 46.3 % and 36.5 % of the patients reported depression and anxiety, respectively. The stepwise multivariate linear regression analysis highlighted that depression(β=-0.638, 95 %CI:0.876∼-0.401, p < 0.05), anxiety(β=-0.508, 95 %CI:0.708∼-0.307, p < 0.05), EDS(β=-0.210, 95 % CI:0.364∼-0.057, p = 0.007), number of antiseizure medications (ASMs)(β=-1.268, 95 % CI:2.318∼-0.217, p = 0.018), insomnia(β=-0.161, 95 % CI:0.292∼-0.030, p = 0.016) and seizure frequency(β=-0.570, 95 % CI:1.129∼-0.011, p = 0.046) were the main factors that influenced the total score of QOLIE-31 in PWE.

Conclusions

PWE showed a high prevalence of sleep disorders, especially insomnia, OSA and EDS, which significantly reduced the QoL of PWE in western China. Addressing sleep and psychiatric disorders might improve the overall QoL of PWE.
{"title":"The impact of sleep disorders on quality of life in patients with epilepsy","authors":"Xiang Huang ,&nbsp;Yingying Zhang ,&nbsp;Qiuxing Lin ,&nbsp;Kailing Huang ,&nbsp;Yuming Li ,&nbsp;Peiwen Liu ,&nbsp;Danyang Cao ,&nbsp;Wenhao Li ,&nbsp;Wei Li ,&nbsp;Dong Zhou ,&nbsp;Dongmei An","doi":"10.1016/j.seizure.2025.04.012","DOIUrl":"10.1016/j.seizure.2025.04.012","url":null,"abstract":"<div><h3>Objective</h3><div>We aimed to explore the prevalence of sleep disorders and their impact on the quality of life (QoL) in patients with epilepsy (PWE) in western China.</div></div><div><h3>Methods</h3><div>This cross-sectional study included PWE aged ≥14 years who were assessed using QoL in epilepsy-31 inventory (QOLIE-31), Insomnia Severity Index (ISI), STOP-BANG questionnaire, Epworth sleepiness scale (ESS), Pittsburgh sleep quality index (PSQI), Chinese version of Neurological Disorders Depression Inventory for Epilepsy (C<img>NDDI-E) and Generalized Anxiety Disorder-7 (GAD-7). The impact of sleep disorders, depression and anxiety on all aspects of QOLIE-31 scores in PWE were assessed.</div></div><div><h3>Results</h3><div>A total of 458 PWE were enrolled. Mean QOLIE-31 score was 51.27±9.69. Relevant assessment scales showed that 10.3 % of the patients suffered from insomnia, 12.9 % of the cohort had a high risk of obstructive sleep apnea (OSA), 33.0 % of the patients had excessive daytime sleepiness (EDS), 48.0 % of the patients reported poor sleep, while 46.3 % and 36.5 % of the patients reported depression and anxiety, respectively. The stepwise multivariate linear regression analysis highlighted that depression(β=-0.638, 95 %CI:0.876∼-0.401, <em>p</em> &lt; 0.05), anxiety(β=-0.508, 95 %CI:0.708∼-0.307, <em>p</em> &lt; 0.05), EDS(β=-0.210, 95 % CI:0.364∼-0.057, <em>p</em> = 0.007), number of antiseizure medications (ASMs)(β=-1.268, 95 % CI:2.318∼-0.217, <em>p</em> = 0.018), insomnia(β=-0.161, 95 % CI:0.292∼-0.030, <em>p</em> = 0.016) and seizure frequency(β=-0.570, 95 % CI:1.129∼-0.011, <em>p</em> = 0.046) were the main factors that influenced the total score of QOLIE-31 in PWE.</div></div><div><h3>Conclusions</h3><div>PWE showed a high prevalence of sleep disorders, especially insomnia, OSA and EDS, which significantly reduced the QoL of PWE in western China. Addressing sleep and psychiatric disorders might improve the overall QoL of PWE.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 115-122"},"PeriodicalIF":2.7,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Problems and needs in everyday life of people with late-onset epilepsy: A scoping review categorization using the international classification of functioning, disability and health (ICF)
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-15 DOI: 10.1016/j.seizure.2025.04.009
Theresa Eberhart , Julia Kämmer , Christoph Ellßel , Daniel Flemming , Helga Pelizäus

Background

Despite an increase in incidence and prevalence of late-onset epilepsy, research on the everyday lives of the people affected is lacking. Understanding the problems and needs of this heterogeneous group of people and their already established coping strategies is essential and guides further research.

Methods

A scoping review following PRISMA-ScR and JBI methodology was conducted to assess the current state of research on the problems and needs of individuals with late-onset epilepsy. Studies were categorized using the World Health Organization (WHO) ICF framework. A literature search (July 2024) was carried out in Medline, CINAHL, PubPsych, and PsycInfo and included individuals aged 65+ with epilepsy, focusing on everyday life and domesticity.

Results

Of 1360 identified records, 14 studies were analyzed. Findings show late-onset epilepsy impairs mental and physical function. The condition can be life-changing, affecting mobility, independence, and social relationships, often leading to isolation and dependence. Managing late-onset epilepsy extends beyond seizure control, necessitating coping strategies, support, effective communication, and addressing comorbidities and seizure unpredictability. The environmental factors influencing late-onset epilepsy include diagnostic tools, treatment options, informal and professional support, attitudes, and care with improved communication and education.

Conclusion

Our scoping review suggests that a multidisciplinary, patient-centered approach is essential to address the substantial mental, physical, and social challenges posed by late-onset epilepsy. This includes enhanced education for patients and healthcare providers, improved communication, and targeted interventions to manage comorbidities, reduce stigma, and improve overall quality of life (QoL).
背景尽管晚发性癫痫的发病率和流行率有所上升,但对患者日常生活的研究却十分缺乏。我们按照 PRISMA-ScR 和 JBI 方法进行了范围综述,以评估有关晚发性癫痫患者的问题和需求的研究现状。研究采用世界卫生组织(WHO)的 ICF 框架进行分类。在 Medline、CINAHL、PubPsych 和 PsycInfo 上进行了文献检索(2024 年 7 月),包括 65 岁以上的癫痫患者,重点关注日常生活和家务。研究结果表明,晚发性癫痫会损害精神和身体功能。这种疾病会改变患者的生活,影响患者的行动能力、独立性和社会关系,往往会导致患者孤立无援和依赖他人。晚发性癫痫的治疗不仅仅局限于控制发作,还需要应对策略、支持、有效沟通以及解决合并症和发作不可预测性等问题。影响晚发性癫痫的环境因素包括诊断工具、治疗方案、非正式和专业的支持、态度以及改善沟通和教育的护理。这包括加强对患者和医疗服务提供者的教育、改善沟通,以及采取有针对性的干预措施来管理并发症、减少耻辱感和改善整体生活质量(QoL)。
{"title":"Problems and needs in everyday life of people with late-onset epilepsy: A scoping review categorization using the international classification of functioning, disability and health (ICF)","authors":"Theresa Eberhart ,&nbsp;Julia Kämmer ,&nbsp;Christoph Ellßel ,&nbsp;Daniel Flemming ,&nbsp;Helga Pelizäus","doi":"10.1016/j.seizure.2025.04.009","DOIUrl":"10.1016/j.seizure.2025.04.009","url":null,"abstract":"<div><h3>Background</h3><div>Despite an increase in incidence and prevalence of late-onset epilepsy, research on the everyday lives of the people affected is lacking. Understanding the problems and needs of this heterogeneous group of people and their already established coping strategies is essential and guides further research.</div></div><div><h3>Methods</h3><div>A scoping review following PRISMA-ScR and JBI methodology was conducted to assess the current state of research on the problems and needs of individuals with late-onset epilepsy. Studies were categorized using the World Health Organization (WHO) ICF framework. A literature search (July 2024) was carried out in Medline, CINAHL, PubPsych, and PsycInfo and included individuals aged 65+ with epilepsy, focusing on everyday life and domesticity.</div></div><div><h3>Results</h3><div>Of 1360 identified records, 14 studies were analyzed. Findings show late-onset epilepsy impairs mental and physical function. The condition can be life-changing, affecting mobility, independence, and social relationships, often leading to isolation and dependence. Managing late-onset epilepsy extends beyond seizure control, necessitating coping strategies, support, effective communication, and addressing comorbidities and seizure unpredictability. The environmental factors influencing late-onset epilepsy include diagnostic tools, treatment options, informal and professional support, attitudes, and care with improved communication and education.</div></div><div><h3>Conclusion</h3><div>Our scoping review suggests that a multidisciplinary, patient-centered approach is essential to address the substantial mental, physical, and social challenges posed by late-onset epilepsy. This includes enhanced education for patients and healthcare providers, improved communication, and targeted interventions to manage comorbidities, reduce stigma, and improve overall quality of life (QoL).</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 88-107"},"PeriodicalIF":2.7,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Super-rapid titration of vagus nerve stimulation in a patient with DEPDC5-related drug-resistant epilepsy
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-12 DOI: 10.1016/j.seizure.2025.04.007
Javier Peña-Ceballos , Breege Staunton-Grufferty , Nicola Dempsey , Ming-Sheng Lim , Patrick B. Moloney , Ronan D. Kilbride , Hany El Naggar , Donncha O'Brien , Norman Delanty , David Lewis-Smith
Pathogenic mutations in DEPDC5 are responsible for a broad range of focal lesional and non-lesional epilepsies. Drug resistance and normal structural neuroimaging findings are common in more than half of patients. Neuromodulation techniques like vagus nerve stimulation (VNS) might be particularly attractive for those patients who are less likely to have a good outcome from surgical resection due to normal neuroimaging or whose epileptogenic zone involves eloquent regions, which if disrupted by resection could leave new deficits. Here, we report the super-rapid titration of stimulation, starting on the day of implantation, of a VNS Model 1000 without complications in an 18-year-old woman with drug-resistant non-lesional DEPDC5-related focal epilepsy experiencing very frequent seizures. This achieved ≥50 % seizure reduction, allowing reduction of the burden of medication.
{"title":"Super-rapid titration of vagus nerve stimulation in a patient with DEPDC5-related drug-resistant epilepsy","authors":"Javier Peña-Ceballos ,&nbsp;Breege Staunton-Grufferty ,&nbsp;Nicola Dempsey ,&nbsp;Ming-Sheng Lim ,&nbsp;Patrick B. Moloney ,&nbsp;Ronan D. Kilbride ,&nbsp;Hany El Naggar ,&nbsp;Donncha O'Brien ,&nbsp;Norman Delanty ,&nbsp;David Lewis-Smith","doi":"10.1016/j.seizure.2025.04.007","DOIUrl":"10.1016/j.seizure.2025.04.007","url":null,"abstract":"<div><div>Pathogenic mutations in <em>DEPDC5</em> are responsible for a broad range of focal lesional and non-lesional epilepsies. Drug resistance and normal structural neuroimaging findings are common in more than half of patients. Neuromodulation techniques like vagus nerve stimulation (VNS) might be particularly attractive for those patients who are less likely to have a good outcome from surgical resection due to normal neuroimaging or whose epileptogenic zone involves eloquent regions, which if disrupted by resection could leave new deficits. Here, we report the <em>super-rapid</em> titration of stimulation, starting on the day of implantation, of a VNS Model 1000 without complications in an 18-year-old woman with drug-resistant non-lesional <em>DEPDC5</em>-related focal epilepsy experiencing very frequent seizures. This achieved ≥50 % seizure reduction, allowing reduction of the burden of medication.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 84-87"},"PeriodicalIF":2.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143838968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A diagnosis and prediction algorithm for juvenile myoclonic epilepsy based on clinical and quantitative EEG features
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-12 DOI: 10.1016/j.seizure.2025.04.006
Yibo Zhao , Qi Wang , Zhe Ren , Bin Wen , Ying Li , Na Wang , Bin Wang , Ting Zhao , Yanan Chen , Pan Zhao , Mingmin Li , Zongya Zhao , Beijia Cui , Jiuyan Han , Yang Hong , Xiong Han

Objective

To develop an objective ensemble machine learning model combining clinical features and quantitative EEG metrics (phase locking value [PLV] and multiscale sample entropy [MSE]) to support accurate diagnosis of juvenile myoclonic epilepsy (JME).

Methods

A total of 75 JME patients, 51 frontal lobe epilepsy (FLE) patients, and 30 normal controls were included. Eight clinical features, along with 684 PLV and 152 MSE features derived from EEG data, were extracted. Four models were constructed using ensemble XGBoost and GBDT classifiers, with performance evaluated through accuracy, precision, recall, F1-score, and AUC. The performance of these models was assessed using a five-fold cross-validation method. The Fisher Score method ranked the most influential features in the best-performing model.

Results

The combined model (clinical, PLV, and MSE features) achieved an accuracy of 85.26 % and an AUC of 0.97. Key features included specific PLV metrics and family history of epilepsy. Notably, the PLV of Fp2-O1 in the δ band (δ-PLV_Fp2-O1) significantly differed among JME, FLE, and normal controls.

Conclusion

The ensemble model effectively distinguished JME, and highlighted δ-PLV_Fp2-O1 as a potential distinguishing feature, paving the way for more objective diagnostic approaches.
{"title":"A diagnosis and prediction algorithm for juvenile myoclonic epilepsy based on clinical and quantitative EEG features","authors":"Yibo Zhao ,&nbsp;Qi Wang ,&nbsp;Zhe Ren ,&nbsp;Bin Wen ,&nbsp;Ying Li ,&nbsp;Na Wang ,&nbsp;Bin Wang ,&nbsp;Ting Zhao ,&nbsp;Yanan Chen ,&nbsp;Pan Zhao ,&nbsp;Mingmin Li ,&nbsp;Zongya Zhao ,&nbsp;Beijia Cui ,&nbsp;Jiuyan Han ,&nbsp;Yang Hong ,&nbsp;Xiong Han","doi":"10.1016/j.seizure.2025.04.006","DOIUrl":"10.1016/j.seizure.2025.04.006","url":null,"abstract":"<div><h3>Objective</h3><div>To develop an objective ensemble machine learning model combining clinical features and quantitative EEG metrics (phase locking value [PLV] and multiscale sample entropy [MSE]) to support accurate diagnosis of juvenile myoclonic epilepsy (JME).</div></div><div><h3>Methods</h3><div>A total of 75 JME patients, 51 frontal lobe epilepsy (FLE) patients, and 30 normal controls were included. Eight clinical features, along with 684 PLV and 152 MSE features derived from EEG data, were extracted. Four models were constructed using ensemble XGBoost and GBDT classifiers, with performance evaluated through accuracy, precision, recall, F1-score, and AUC. The performance of these models was assessed using a five-fold cross-validation method. The Fisher Score method ranked the most influential features in the best-performing model.</div></div><div><h3>Results</h3><div>The combined model (clinical, PLV, and MSE features) achieved an accuracy of 85.26 % and an AUC of 0.97. Key features included specific PLV metrics and family history of epilepsy. Notably, the PLV of Fp2-O1 in the δ band (δ-PLV_Fp2-O1) significantly differed among JME, FLE, and normal controls.</div></div><div><h3>Conclusion</h3><div>The ensemble model effectively distinguished JME, and highlighted δ-PLV_Fp2-O1 as a potential distinguishing feature, paving the way for more objective diagnostic approaches.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 59-69"},"PeriodicalIF":2.7,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Levetiracetam-induced seizure aggravation-case series and literature review
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-10 DOI: 10.1016/j.seizure.2025.04.005
Tal Friedman-Korn , Tal Benoliel-Berman , Diya Doufish , Tzlil Shifman , Mordekhay Medvedovsky , Dana Ekstein

Purpose

Levetiracetam (LEV) is often a first-line epilepsy treatment due to its broad efficacy and favorable side effect profile. While LEV-induced seizure aggravation (LISA) has been reported in up to 18 % of LEV users in certain patient populations, the risk factors for LISA have not been well delineated. This study aims to provide a comprehensive assessment of seizure aggravation associated with LEV.

Methods

We conducted a comprehensive literature review of LISA case reports and case series. Additionally, we report a case series of seven patients treated at Hadassah Medical Center from 2015 to 2025 who experienced LISA.

Results

Our literature review identified 26 papers comprising 143 patient descriptions of LISA. Patients were 9 months to 80 years old, and seizure aggravation manifested as increased seizure frequency, status epilepticus, and the appearance of non-habitual seizures. Patients had both focal and generalized epilepsy, secondary to a variety of underlying lesion, and genetic mutation. LEV dosing ranged from 500 to 4500 mg per day. All patients in our case series experienced increased seizure frequency during LEV treatment, with two patients developing epilepsia partialis continua. Reducing or stopping LEV decreased seizures, sometimes leading to seizure freedom.

Conclusion

We found that LISA can occur across different age groups, epilepsy types and underlying etiologies. Clinicians should consider LISA in the differential diagnosis of seizure exacerbation following LEV treatment and evaluate the potential benefits of LEV discontinuation. Further studies are needed to determine the occurrence and risk factors of LISA to optimize ASM treatment.
{"title":"Levetiracetam-induced seizure aggravation-case series and literature review","authors":"Tal Friedman-Korn ,&nbsp;Tal Benoliel-Berman ,&nbsp;Diya Doufish ,&nbsp;Tzlil Shifman ,&nbsp;Mordekhay Medvedovsky ,&nbsp;Dana Ekstein","doi":"10.1016/j.seizure.2025.04.005","DOIUrl":"10.1016/j.seizure.2025.04.005","url":null,"abstract":"<div><h3>Purpose</h3><div>Levetiracetam (LEV) is often a first-line epilepsy treatment due to its broad efficacy and favorable side effect profile. While LEV-induced seizure aggravation (LISA) has been reported in up to 18 % of LEV users in certain patient populations, the risk factors for LISA have not been well delineated. This study aims to provide a comprehensive assessment of seizure aggravation associated with LEV.</div></div><div><h3>Methods</h3><div>We conducted a comprehensive literature review of LISA case reports and case series. Additionally, we report a case series of seven patients treated at Hadassah Medical Center from 2015 to 2025 who experienced LISA.</div></div><div><h3>Results</h3><div>Our literature review identified 26 papers comprising 143 patient descriptions of LISA. Patients were 9 months to 80 years old, and seizure aggravation manifested as increased seizure frequency, status epilepticus, and the appearance of non-habitual seizures. Patients had both focal and generalized epilepsy, secondary to a variety of underlying lesion, and genetic mutation. LEV dosing ranged from 500 to 4500 mg per day. All patients in our case series experienced increased seizure frequency during LEV treatment, with two patients developing epilepsia partialis continua. Reducing or stopping LEV decreased seizures, sometimes leading to seizure freedom.</div></div><div><h3>Conclusion</h3><div>We found that LISA can occur across different age groups, epilepsy types and underlying etiologies. Clinicians should consider LISA in the differential diagnosis of seizure exacerbation following LEV treatment and evaluate the potential benefits of LEV discontinuation. Further studies are needed to determine the occurrence and risk factors of LISA to optimize ASM treatment.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 77-83"},"PeriodicalIF":2.7,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143838967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors influencing neurologists' prescribing of antiseizure medication: The role of physician biography and patient characteristics
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-09 DOI: 10.1016/j.seizure.2025.04.004
Jenny Stritzelberger , Katrin Walther , David Olmes , Stephanie Gollwitzer , Tamara M. Welte , Johannes D. Lang , Caroline Reindl , Stefan Schwab , Peter Kriwy , Hajo M. Hamer

Objective

Although committed to equal treatment, physicians may be influenced by various non-medical factors when deciding how to treat patients and allocate treatment costs. This study examines how biographical factors and patient characteristics influence physicians’ decisions in the context of antiseizure medication (ASM) prescriptions.

Methods

We re-analysed a cohort from a previous factorial study focusing on physicians’ characteristics. Vignettes showed a fictitious person with epilepsy (PWE) receiving a fictitious ASM. The characteristics of the PWE, the ASM and the epilepsy varied. We asked neurologists to rate the likelihood that they would prescribe the drug to the patient, and to complete a survey on personal characteristics (including age, sex, living situation, professional experience and contact with PWE).

Results

46 neurologists (age 37.1 ± 9.6 years, 65.2 % female) completed the questionnaire. Neurologists who rated themselves as being in the best possible health state or who had private contact with PWE were more likely to prescribe ASM.

Conclusion

Neurologists’ biographies and experiences influenced their decisions about the likelihood of prescribing ASM therapy.
{"title":"Factors influencing neurologists' prescribing of antiseizure medication: The role of physician biography and patient characteristics","authors":"Jenny Stritzelberger ,&nbsp;Katrin Walther ,&nbsp;David Olmes ,&nbsp;Stephanie Gollwitzer ,&nbsp;Tamara M. Welte ,&nbsp;Johannes D. Lang ,&nbsp;Caroline Reindl ,&nbsp;Stefan Schwab ,&nbsp;Peter Kriwy ,&nbsp;Hajo M. Hamer","doi":"10.1016/j.seizure.2025.04.004","DOIUrl":"10.1016/j.seizure.2025.04.004","url":null,"abstract":"<div><h3>Objective</h3><div>Although committed to equal treatment, physicians may be influenced by various non-medical factors when deciding how to treat patients and allocate treatment costs. This study examines how biographical factors and patient characteristics influence physicians’ decisions in the context of antiseizure medication (ASM) prescriptions.</div></div><div><h3>Methods</h3><div>We re-analysed a cohort from a previous factorial study focusing on physicians’ characteristics. Vignettes showed a fictitious person with epilepsy (PWE) receiving a fictitious ASM. The characteristics of the PWE, the ASM and the epilepsy varied. We asked neurologists to rate the likelihood that they would prescribe the drug to the patient, and to complete a survey on personal characteristics (including age, sex, living situation, professional experience and contact with PWE).</div></div><div><h3>Results</h3><div>46 neurologists (age 37.1 ± 9.6 years, 65.2 % female) completed the questionnaire. Neurologists who rated themselves as being in the best possible health state or who had private contact with PWE were more likely to prescribe ASM.</div></div><div><h3>Conclusion</h3><div>Neurologists’ biographies and experiences influenced their decisions about the likelihood of prescribing ASM therapy.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 55-58"},"PeriodicalIF":2.7,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostics and Non-pharmacological interventions for refractory and super refractory status epilepticus in Germany: A comprehensive analysis of 4 years of billing data 德国难治性和超难治性癫痫状态的诊断和非药物干预:对 4 年收费数据的综合分析
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-08 DOI: 10.1016/j.seizure.2025.04.003
Larissa Fink , Berthold Voges , Marcel A. Kamp , Christiane von Saß , Maxine Dibué

Background

Status epilepticus (SE) is a critical neurological emergency, with its most severe form, refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE), posing significant treatment challenges and high mortality rates. Despite robust early-phase treatment evidence, effective management of RSE and SRSE remains less defined.

Objective

This study aimed to assess the incidence of potential RSE and SRSE in Germany from 2019 to 2022, evaluate diagnostic and non-pharmacological interventions, and analyze associated healthcare costs.

Methods

A cross-sectional retrospective analysis was conducted using data from the Institute for the Hospital Remuneration System (InEK). Cases were identified using ICD-10 code G41 and included patients who underwent mechanical ventilation for at least one hour. Data on demographics, diagnostic procedures, therapeutic interventions, discharge outcomes, and healthcare costs were extracted and analyzed.

Results

Between 2019 and 2022, 89,921 SE cases were identified, with 21,729 (24.2 %) progressing to potential RSE or SRSE. Male patients comprised 56 % of these cases. The majority of cases occurred in patients aged 65–74 years. The overall mortality or hospice transfer rate for potential RSE/SRSE cases was 33.7 %. Common diagnostic procedures included EEG (80 %) and CT scans (113 %), while non-pharmacological interventions such as hypothermia therapy were used in 10 % of cases, and plasmapheresis was employed in 1 %. Electroconvulsive therapy, vagus nerve stimulation, deep brain stimulation, transcranial magnetic stimulation, ketogenic diet, resection of foreign tissue from the brain, and epilepsy surgery were not performed at all. 4 % of the patients who died in the hospital or were discharged to a hospice received interventions in a palliative care setting. The total estimated cost for potential RSE/SRSE cases in 2022 was approximately €44.24 million, highlighting the economic burden on the healthcare system.

Conclusion

The study underscores the need for improved diagnostic and therapeutic strategies in managing RSE and SRSE. It also calls for exploration of non-pharmacological treatments to reduce the high mortality and economic costs associated with these conditions. Further research is essential to establish evidence-based protocols for RSE and SRSE management.
{"title":"Diagnostics and Non-pharmacological interventions for refractory and super refractory status epilepticus in Germany: A comprehensive analysis of 4 years of billing data","authors":"Larissa Fink ,&nbsp;Berthold Voges ,&nbsp;Marcel A. Kamp ,&nbsp;Christiane von Saß ,&nbsp;Maxine Dibué","doi":"10.1016/j.seizure.2025.04.003","DOIUrl":"10.1016/j.seizure.2025.04.003","url":null,"abstract":"<div><h3>Background</h3><div>Status epilepticus (SE) is a critical neurological emergency, with its most severe form, refractory status epilepticus (RSE) and super-refractory status epilepticus (SRSE), posing significant treatment challenges and high mortality rates. Despite robust early-phase treatment evidence, effective management of RSE and SRSE remains less defined.</div></div><div><h3>Objective</h3><div>This study aimed to assess the incidence of potential RSE and SRSE in Germany from 2019 to 2022, evaluate diagnostic and non-pharmacological interventions, and analyze associated healthcare costs.</div></div><div><h3>Methods</h3><div>A cross-sectional retrospective analysis was conducted using data from the Institute for the Hospital Remuneration System (InEK). Cases were identified using ICD-10 code G41 and included patients who underwent mechanical ventilation for at least one hour. Data on demographics, diagnostic procedures, therapeutic interventions, discharge outcomes, and healthcare costs were extracted and analyzed.</div></div><div><h3>Results</h3><div>Between 2019 and 2022, 89,921 SE cases were identified, with 21,729 (24.2 %) progressing to potential RSE or SRSE. Male patients comprised 56 % of these cases. The majority of cases occurred in patients aged 65–74 years. The overall mortality or hospice transfer rate for potential RSE/SRSE cases was 33.7 %. Common diagnostic procedures included EEG (80 %) and CT scans (113 %), while non-pharmacological interventions such as hypothermia therapy were used in 10 % of cases, and plasmapheresis was employed in 1 %. Electroconvulsive therapy, vagus nerve stimulation, deep brain stimulation, transcranial magnetic stimulation, ketogenic diet, resection of foreign tissue from the brain, and epilepsy surgery were not performed at all. 4 % of the patients who died in the hospital or were discharged to a hospice received interventions in a palliative care setting. The total estimated cost for potential RSE/SRSE cases in 2022 was approximately €44.24 million, highlighting the economic burden on the healthcare system.</div></div><div><h3>Conclusion</h3><div>The study underscores the need for improved diagnostic and therapeutic strategies in managing RSE and SRSE. It also calls for exploration of non-pharmacological treatments to reduce the high mortality and economic costs associated with these conditions. Further research is essential to establish evidence-based protocols for RSE and SRSE management.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 108-114"},"PeriodicalIF":2.7,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143864709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What extent of adverse drug reactions seems acceptable for what degree of seizure reduction in paediatric patients with epilepsy?—An exploratory study on the parents' perspective
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-02 DOI: 10.1016/j.seizure.2025.04.002
Martina P. Neininger , Esther Meise , Sarah Jeschke , Samuel Tomczyk , Silke Schmidt-Schuchert , Thilo Bertsche , Astrid Bertsche
Purpose We aimed to explore the perspectives of parents of children with epilepsy regarding the extent of adverse drug reactions (ADRs) of antiseizure medications (ASMs) they are willing to accept for a certain degree of seizure reduction.
Methods We presented a table showing two levels of the likelihood of occurrence (low/high) and two levels of severity (mild/severe) for a number of ADRs including irritability, impairment of attention, and fatigue. For each combination of likelihood and severity, 98 parents were asked to indicate the degree of seizure reduction for which they were willing to accept the given ADR.
Results Even in exchange for seizure-freedom, severe irritability occurring with a high likelihood was unacceptable to 53 % of parents. This applied to 51 % concerning impairment of attention, and to 40 % concerning fatigue. At 50 % seizure reduction, 2 % of parents were willing to accept a high likelihood of occurrence of severe irritability. This applied to 5 % of parents concerning impairment of attention, and 9 % of parents concerning fatigue. With regard to mild forms of ADRs very likely to occur, 16 % of parents considered impairment of attention to be unacceptable despite seizure freedom; this applied to 12 % of parents for irritability, and 6 % of parents for fatigue.
Conclusion Even for seizure freedom or a major reduction in seizures, parents often refused to accept ADRs. Therefore, it is important to consider the parents’ perspective when choosing an ASM, and to find the optimal balance between desired effectiveness and ADRs acceptable to parents and paediatric patients.
{"title":"What extent of adverse drug reactions seems acceptable for what degree of seizure reduction in paediatric patients with epilepsy?—An exploratory study on the parents' perspective","authors":"Martina P. Neininger ,&nbsp;Esther Meise ,&nbsp;Sarah Jeschke ,&nbsp;Samuel Tomczyk ,&nbsp;Silke Schmidt-Schuchert ,&nbsp;Thilo Bertsche ,&nbsp;Astrid Bertsche","doi":"10.1016/j.seizure.2025.04.002","DOIUrl":"10.1016/j.seizure.2025.04.002","url":null,"abstract":"<div><div>Purpose We aimed to explore the perspectives of parents of children with epilepsy regarding the extent of adverse drug reactions (ADRs) of antiseizure medications (ASMs) they are willing to accept for a certain degree of seizure reduction.</div><div>Methods We presented a table showing two levels of the likelihood of occurrence (low/high) and two levels of severity (mild/severe) for a number of ADRs including irritability, impairment of attention, and fatigue. For each combination of likelihood and severity, 98 parents were asked to indicate the degree of seizure reduction for which they were willing to accept the given ADR.</div><div>Results Even in exchange for seizure-freedom, severe irritability occurring with a high likelihood was unacceptable to 53 % of parents. This applied to 51 % concerning impairment of attention, and to 40 % concerning fatigue. At 50 % seizure reduction, 2 % of parents were willing to accept a high likelihood of occurrence of severe irritability. This applied to 5 % of parents concerning impairment of attention, and 9 % of parents concerning fatigue. With regard to mild forms of ADRs very likely to occur, 16 % of parents considered impairment of attention to be unacceptable despite seizure freedom; this applied to 12 % of parents for irritability, and 6 % of parents for fatigue.</div><div>Conclusion Even for seizure freedom or a major reduction in seizures, parents often refused to accept ADRs. Therefore, it is important to consider the parents’ perspective when choosing an ASM, and to find the optimal balance between desired effectiveness and ADRs acceptable to parents and paediatric patients.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 29-32"},"PeriodicalIF":2.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143785220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stereoelectroencephalography versus subdural electrodes for invasive monitoring of drug-resistant epilepsy patients: a systematic review and meta-analysis
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-02 DOI: 10.1016/j.seizure.2025.04.001
Fernando Cotrim Gomes , Anna Laura Lima Larcipretti , Ofonime Chantal Udoma-Udofa , Bárbara Alves de Abreu Rocha , Maria Eduarda Bezerra Mota , Mateus Machado Decina , Júlia Oliveira Dabien Haddad , Matheus de Andrade Bannach , Niels Pacheco-Barrios , John D. Rolston

Introduction

Invasive monitoring for epilepsy surgery is critical for localizing epileptogenic zones. Stereoelectroencephalography (SEEG) and subdural electrodes (SDE) are two primary techniques used for this purpose. This meta-analysis aims to compare the effectiveness and safety of SEEG and SDE regarding various clinical outcomes in patients undergoing invasive epilepsy monitoring.

Methods

We conducted a systematic review and meta-analysis of studies comparing SEEG and SDE for invasive epilepsy monitoring. PubMed, Embase, and Cochrane Library databases were searched for relevant studies. Two reviewers performed data extraction and quality assessment through Cochrane's ROBINS-I tool independently. Statistical analyses were conducted using a random-effects model in R Studio.

Results

A total of 16 studies involving 3751 patients were included in the analysis, with 1750 who underwent SDE and 2001 in the SEEG group. There was no statistically significant difference between groups regarding seizure freedom at last follow-up (OR 1.05; 95 % CI 0.61–1.81; I2 = 56 %; p = 0.86). The SEEG group, however, was associated with lower incidence of complications (OR 0.50; 95 %CI 0.28, 0.91; I2 74 %; p < 0.01), fewer major bleeding events (OR 0.23; 95 %CI 0.11, 0.49; I2 0 %; p < 0.01), fewer post-operative neurological deficits (OR 0.39; 95 %CI 0.21, 0.73; I2 23 %; p < 0.05), and shorter operative time (MD -76.28 min; 95 %CI -101.86, -50.70; I2 92 %; p < 0.05).

Conclusion

SEEG and SDE are both effective in achieving seizure freedom for drug-resistant epilepsy patients undergoing invasive monitoring. SEEG may offer advantages in terms of safety and healthcare utilization, with fewer complications and shorter operative times. These findings support the growing adoption of SEEG as a preferred method for epilepsy surgery, though further prospective studies are needed to validate these results.
{"title":"Stereoelectroencephalography versus subdural electrodes for invasive monitoring of drug-resistant epilepsy patients: a systematic review and meta-analysis","authors":"Fernando Cotrim Gomes ,&nbsp;Anna Laura Lima Larcipretti ,&nbsp;Ofonime Chantal Udoma-Udofa ,&nbsp;Bárbara Alves de Abreu Rocha ,&nbsp;Maria Eduarda Bezerra Mota ,&nbsp;Mateus Machado Decina ,&nbsp;Júlia Oliveira Dabien Haddad ,&nbsp;Matheus de Andrade Bannach ,&nbsp;Niels Pacheco-Barrios ,&nbsp;John D. Rolston","doi":"10.1016/j.seizure.2025.04.001","DOIUrl":"10.1016/j.seizure.2025.04.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Invasive monitoring for epilepsy surgery is critical for localizing epileptogenic zones. Stereoelectroencephalography (SEEG) and subdural electrodes (SDE) are two primary techniques used for this purpose. This meta-analysis aims to compare the effectiveness and safety of SEEG and SDE regarding various clinical outcomes in patients undergoing invasive epilepsy monitoring.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of studies comparing SEEG and SDE for invasive epilepsy monitoring. PubMed, Embase, and Cochrane Library databases were searched for relevant studies. Two reviewers performed data extraction and quality assessment through Cochrane's ROBINS-I tool independently. Statistical analyses were conducted using a random-effects model in R Studio.</div></div><div><h3>Results</h3><div>A total of 16 studies involving 3751 patients were included in the analysis, with 1750 who underwent SDE and 2001 in the SEEG group. There was no statistically significant difference between groups regarding seizure freedom at last follow-up (OR 1.05; 95 % CI 0.61–1.81; I2 = 56 %; <em>p</em> = 0.86). The SEEG group, however, was associated with lower incidence of complications (OR 0.50; 95 %CI 0.28, 0.91; I<sup>2</sup> 74 %; <em>p</em> &lt; 0.01), fewer major bleeding events (OR 0.23; 95 %CI 0.11, 0.49; I<sup>2</sup> 0 %; <em>p</em> &lt; 0.01), fewer post-operative neurological deficits (OR 0.39; 95 %CI 0.21, 0.73; I<sup>2</sup> 23 %; <em>p</em> &lt; 0.05), and shorter operative time (MD -76.28 min; 95 %CI -101.86, -50.70; I<sup>2</sup> 92 %; <em>p</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>SEEG and SDE are both effective in achieving seizure freedom for drug-resistant epilepsy patients undergoing invasive monitoring. SEEG may offer advantages in terms of safety and healthcare utilization, with fewer complications and shorter operative times. These findings support the growing adoption of SEEG as a preferred method for epilepsy surgery, though further prospective studies are needed to validate these results.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 33-41"},"PeriodicalIF":2.7,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143799688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A real-world comparison between the diagnostic yield of trio-whole exome sequencing and proband-only targeted exome sequencing in complex childhood epilepsy
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2025-04-01 DOI: 10.1016/j.seizure.2025.03.020
Alfiya Fasaludeen , Manna Jose , Aswathi U , Surabhi Prasannakumar , Moinak Banerjee , Soumya Sundaram , Madhusoodanan UK , Ashalatha Radhakrishnan , Ramshekhar N Menon

Purpose

Exome sequencing is the preferred method for the molecular diagnosis of childhood drug-resistant epilepsies (DRE) of uncertain etiology, particularly the developmental and epileptic encephalopathies (DEE) with a challenge being genotype-phenotype heterogeneity. This study assesses the diagnostic utility of trio-whole exome sequencing (trio-WES) over a panel-based targeted exome sequencing (TES).

Methods

We performed genetic testing in 400 probands (age of onset <12 years) who had been diagnosed with complex pediatric epilepsy syndromes (refractory focal/generalized epilepsies of uncertain etiology and DEE). Among the 400 probands, 158 underwent trio-WES and 242 underwent TES.

Results

The overall yield of pathogenic/likely pathogenic variants was similar, at 42.1 % for 242 patients who underwent TES and 42.4 % for 158 patients with trio-WES. However, among 67 disease causing variants identified by trio-WES, 67.2 % were established as de novo at baseline evaluation. A major highlight is that trio-WES achieved a diagnosis in 10 (35.7 %) of 28 patients with inconclusive/negative TES. The cost analysis shows that trio-WES ($534) is probably the more cost-effective method in early childhood wherein de novo pathogenic variants are likely to be causative, as ordering it after negative or inconclusive TES results will have an added cost.

Conclusion

This study demonstrates real world utility of trio-WES as a useful and cost-efficient tool for determining de novo genetic etiologies for unexplained childhood DRE phenotypes.
{"title":"A real-world comparison between the diagnostic yield of trio-whole exome sequencing and proband-only targeted exome sequencing in complex childhood epilepsy","authors":"Alfiya Fasaludeen ,&nbsp;Manna Jose ,&nbsp;Aswathi U ,&nbsp;Surabhi Prasannakumar ,&nbsp;Moinak Banerjee ,&nbsp;Soumya Sundaram ,&nbsp;Madhusoodanan UK ,&nbsp;Ashalatha Radhakrishnan ,&nbsp;Ramshekhar N Menon","doi":"10.1016/j.seizure.2025.03.020","DOIUrl":"10.1016/j.seizure.2025.03.020","url":null,"abstract":"<div><h3>Purpose</h3><div>Exome sequencing is the preferred method for the molecular diagnosis of childhood drug-resistant epilepsies (DRE) of uncertain etiology, particularly the developmental and epileptic encephalopathies (DEE) with a challenge being genotype-phenotype heterogeneity. This study assesses the diagnostic utility of trio-whole exome sequencing (trio-WES) over a panel-based targeted exome sequencing (TES).</div></div><div><h3>Methods</h3><div>We performed genetic testing in 400 probands (age of onset &lt;12 years) who had been diagnosed with complex pediatric epilepsy syndromes (refractory focal/generalized epilepsies of uncertain etiology and DEE). Among the 400 probands, 158 underwent trio-WES and 242 underwent TES.</div></div><div><h3>Results</h3><div>The overall yield of pathogenic/likely pathogenic variants was similar, at 42.1 % for 242 patients who underwent TES and 42.4 % for 158 patients with trio-WES. However, among 67 disease causing variants identified by trio-WES, 67.2 % were established as <em>de novo</em> at baseline evaluation. A major highlight is that trio-WES achieved a diagnosis in 10 (35.7 %) of 28 patients with inconclusive/negative TES. The cost analysis shows that trio-WES ($534) is probably the more cost-effective method in early childhood wherein <em>de novo</em> pathogenic variants are likely to be causative, as ordering it after negative or inconclusive TES results will have an added cost.</div></div><div><h3>Conclusion</h3><div>This study demonstrates real world utility of trio-WES as a useful and cost-efficient tool for determining <em>de novo</em> genetic etiologies for unexplained childhood DRE phenotypes.</div></div>","PeriodicalId":49552,"journal":{"name":"Seizure-European Journal of Epilepsy","volume":"129 ","pages":"Pages 51-54"},"PeriodicalIF":2.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143823815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seizure-European Journal of Epilepsy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1